Overview

A Study in Erectile Dysfunction

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Phosphodiesterase 5 Inhibitors
Tadalafil